On June 27, 2025, Abeona Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher for $155 million, following its award by the FDA on April 28, 2025. As of June 30, 2025, the company's total cash and investments reached approximately $225 million.